Medical Cannabis for ADHD UK: Can It Help?

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition characterised by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with daily functioning. It affects approximately 2.6 million people in the UK — around 5% of children and 3–4% of adults — making it one of the most prevalent neurodevelopmental conditions in the country.

Despite its prevalence, ADHD remains significantly underdiagnosed, particularly in women and girls. NHS waiting lists for adult ADHD assessment now commonly exceed two years in many regions, leaving many patients without formal diagnosis or treatment for extended periods. For those who do receive a diagnosis, first-line treatments include stimulant medications such as methylphenidate (Ritalin, Concerta) and lisdexamfetamine (Vyvanse), as well as non-stimulant options such as atomoxetine. However, a meaningful proportion of patients — estimated at 20–30% — do not respond adequately to these treatments, or experience side effects that make long-term use unsustainable.

The relationship between the endocannabinoid system (ECS) and ADHD is an active area of research. The ECS plays a key role in regulating dopamine and noradrenaline signalling — the same neurotransmitter pathways targeted by conventional ADHD medications. Dysregulation of the ECS has been proposed as a contributing factor in ADHD symptomatology, which provides a plausible biological rationale for cannabinoid-based treatment.

Cannabidiol (CBD), the non-psychoactive cannabinoid, has demonstrated anxiolytic and neuroprotective properties in preclinical and clinical studies. For ADHD patients whose symptoms are compounded by anxiety, emotional dysregulation, and sleep disturbance — all common comorbidities — CBD-dominant preparations may offer meaningful relief. Tetrahydrocannabinol (THC), the psychoactive cannabinoid, has shown some evidence of improving focus and reducing hyperactivity in small clinical studies, though its use requires careful titration and clinical supervision due to its psychoactive effects.

It is important to note that cannabis-based medicines are not a first-line treatment for ADHD. They are considered for patients who have tried and failed at least two conventional treatments, in line with the UK's treatment-resistant pathway for cannabis-based medicinal products (CBMPs).

The evidence base for medical cannabis in ADHD is still developing, but several studies and real-world data sources provide encouraging signals.

A 2020 observational study published in the Journal of Attention Disorders found that adults with ADHD who used cannabis reported significant reductions in inattention and hyperactivity symptoms, as well as improvements in sleep quality and emotional regulation. A 2022 study from the UK Medical Cannabis Registry — one of the largest real-world datasets of CBMP patients in the world — found that ADHD patients treated with CBMPs reported statistically significant improvements in anxiety, sleep, and quality of life scores after three months of treatment.

A small randomised controlled trial (Strohbeck-Kuehner et al.) found that THC improved cognitive performance and behaviour in adults with ADHD, with participants reporting improved concentration and reduced impulsivity. While the trial was limited in size, it was notable as one of the first placebo-controlled studies in this area.

The NICE guidelines on ADHD (NG87) do not currently recommend cannabis-based medicines as a standard treatment, reflecting the limited scale of the evidence base rather than evidence of harm. However, specialist clinicians in the UK are permitted to prescribe CBMPs for ADHD on a case-by-case basis where conventional treatments have been inadequate.

To be considered for a cannabis-based medicinal product for ADHD in the UK, you will generally need to meet the following criteria:

• A confirmed diagnosis of ADHD from a qualified psychiatrist or specialist
• Evidence that you have tried at least two conventional ADHD medications (e.g. methylphenidate and lisdexamfetamine, or atomoxetine) without adequate benefit, or that you have experienced intolerable side effects
• You are aged 18 or over (paediatric prescribing of CBMPs for ADHD is subject to additional restrictions)
• You are a UK resident

You will need to provide your diagnostic report and a summary of your treatment history at your initial consultation. GP letters and specialist correspondence are also helpful. Our [ADHD condition page](/conditions/adhd) provides a detailed overview of the eligibility pathway and what to expect from the assessment process.

Patients with comorbid anxiety, depression, or sleep disorders may find that a CBD-dominant preparation addresses multiple symptoms simultaneously, which can be discussed with your prescribing clinician.

The specific product prescribed will depend on your individual symptom profile, medical history, and the clinical judgement of your specialist. Common formulations used for ADHD include:

CBD-dominant oils and capsules: These are typically the first-line CBMP for ADHD, particularly where anxiety and sleep disturbance are prominent. They are non-psychoactive and well-tolerated by most patients.

Balanced CBD:THC preparations: For patients with more pronounced attentional difficulties, a preparation containing both CBD and THC in a balanced ratio may be considered. These require more careful titration and ongoing monitoring.

THC-dominant preparations: Less commonly used for ADHD due to the risk of exacerbating anxiety in some patients, but may be appropriate in specific clinical contexts under close supervision.

All products dispensed by MEDCANN Pharmacy are pharmaceutical-grade CBMPs manufactured to GMP standards. Your pharmacist will provide full guidance on dosing, administration, and what to expect during the initial titration period.

The process for accessing medical cannabis for ADHD through MEDCANN Pharmacy follows the same pathway as for other conditions:

1. Register as a patient using our online registration form. You will be asked to provide your medical history and details of previous ADHD treatments.
2. Book an initial consultation (£200) with one of our specialist clinicians. The consultation takes place via video call and typically lasts 30–45 minutes.
3. Receive your prescription. If the clinician determines that a CBMP is appropriate, they will issue a private prescription which is sent directly to MEDCANN Pharmacy.
4. Your medication is dispensed and delivered discreetly and securely to your address anywhere in the UK, typically within 2–3 working days.
5. Ongoing monitoring. Follow-up consultations (£95 per quarter) are required to review your response to treatment and renew your prescription.

If you have questions before registering, our pharmacists are available by phone (0208 123 8883) or email ([email protected]) to discuss whether medical cannabis may be appropriate for your situation.

Will medical cannabis make me feel 'high'? Not necessarily. CBD-dominant preparations — which are commonly prescribed for ADHD — are non-psychoactive. If a preparation containing THC is prescribed, your clinician will start at the lowest effective dose and titrate slowly to minimise psychoactive effects while achieving therapeutic benefit.

Can I take medical cannabis alongside my existing ADHD medication? This depends on your specific medications and clinical situation. Potential interactions between CBMPs and stimulant medications will be carefully reviewed by your prescribing clinician. In many cases, CBMPs are used as an adjunct to, rather than a replacement for, existing treatment.

Is medical cannabis for ADHD available on the NHS? No. NHS prescriptions for CBMPs for ADHD are not currently available. This is a private treatment. MEDCANN Pharmacy is committed to transparent pricing — see our [pricing page](/pricing) for a full breakdown of consultation and medication costs.

Will using medical cannabis affect my driving? You must not drive while impaired by any substance, including cannabis. If your prescription contains THC, you should not drive until you understand how the medication affects you. See our detailed guide on [driving and medical cannabis in the UK](/blog/driving-medical-cannabis-uk-law) for full guidance.